Clinical Trials Browser

Phase 1/2 × Liver Neoplasms × tremelimumab × Clear all

NCT06608940 2026-02-19

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Phase 1/2 Withdrawn

Gastrointestinal

Liver Neoplasms

NCT01853618 2019-12-10

Tremelimumab With Chemoembolization or Ablation for Liver Cancer

Phase 1/2 Completed

61 enrolled 18 charts

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms